These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 27148273)

  • 1. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1.
    Zietek T; Rath E
    Front Immunol; 2016; 7():154. PubMed ID: 27148273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Incretin Hormones in Bowel Diseases.
    Zietek T; Waldschmitt N; Rath E
    Endocr Dev; 2017; 32():49-73. PubMed ID: 28873384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretins.
    Wu T; Rayner CK; Horowitz M
    Handb Exp Pharmacol; 2016; 233():137-71. PubMed ID: 25903418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
    Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
    Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unfolded protein responses in the intestinal epithelium: sensors for the microbial and metabolic environment.
    Rath E; Haller D
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S3-5. PubMed ID: 22955354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
    Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
    Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal nutrient sensing and blood glucose control.
    Zietek T; Daniel H
    Curr Opin Clin Nutr Metab Care; 2015 Jul; 18(4):381-8. PubMed ID: 26001654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E; Dworzecki T
    Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the science of incretin biology.
    Nauck MA
    Eur J Intern Med; 2009 Jul; 20 Suppl 2():S303-8. PubMed ID: 19580949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the science of incretin biology.
    Nauck MA
    Am J Med; 2009 Jun; 122(6 Suppl):S3-S10. PubMed ID: 19464426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.
    Lee YS; Jun HS
    Mediators Inflamm; 2016; 2016():3094642. PubMed ID: 27110066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation.
    McPhee JB; Schertzer JD
    Clin Sci (Lond); 2015 Dec; 129(12):1083-96. PubMed ID: 26464517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
    Opinto G; Natalicchio A; Marchetti P
    Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.